Clinical commissioning policy statement: Selective Internal Radiotherapy (SIRT) in the treatment of secondary liver cancers (all ages)

Document first published:
Page updated:
Topic:
Publication type:

Selective Internal Radiotherapy (SIRT) is not recommended to be available as a routine commissioning treatment option for the treatment of (1) neuroendocrine tumour liver metastases (NETLM); (2) liver metastases of other less common radiotherapy sensitive tumours, within the criteria set out in this document.

Document

Clinical commissioning policy statement: Selective Internal Radiotherapy (SIRT) in the treatment of secondary liver cancers (all ages)

Clinical commissioning policy statement: Selective Internal Radiotherapy (SIRT) in the treatment of secondary liver cancers (all ages)

  • PDF
  • 141 KB
  • 6 pages

Summary

Updated January 2024.